Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 8 de 8
Filtrar
1.
Braz. j. biol ; 83: e250000, 2023. graf
Artigo em Inglês | LILACS, VETINDEX | ID: biblio-1339398
3.
Braz. j. biol ; 832023.
Artigo em Inglês | LILACS-Express | LILACS, VETINDEX | ID: biblio-1469218
4.
Braz J Biol ; 83: e250000, 2021.
Artigo em Inglês | MEDLINE | ID: mdl-34524375
5.
BJOG ; 125(10): 1226-1233, 2018 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-29782064

RESUMO

BACKGROUND: Distinguishing hydatidiform moles (HMs) from nonmolar specimens and the subclassification of HM are important because complete hydatidiform mole (CHM) is associated with an increased risk of development of gestational trophoblastic neoplasia. However, diagnosis based solely on morphology has poor inter-observer reproducibility. Recent studies have demonstrated that the use of p57KIP2 immunostaining improves diagnostic accuracy for CHM. OBJECTIVES: To evaluate the accuracy of p57KIP2 immunostaining compared with molecular genotyping for the diagnosis of CHM. SEARCH STRATEGY: Major databases were searched from inception to March 2017 using the terms 'hydatidiform mole', 'p57', and 'genotyping', with their variations, and the search limit for the relevant study design. SELECTION CRITERIA: Any cross-sectional study, case series, case-control study, cohort study, or clinical trial that evaluated the accuracy of p57KIP2 immunostaining for the diagnosis of CHM compared with genotyping was included. Case reports, narrative reviews, expert opinions, and animal testing were excluded. DATA COLLECTION AND ANALYSIS: Extracted accuracy data were tabulated and pooled using a hierarchical bivariate random effects model. MAIN RESULTS: Bivariate meta-analysis produced a summary sensitivity of 0.984 (95% CI: 0.916-1.000) and specificity of 0.625 (95% CI: 0.503-0.736) with significant heterogeneity for specificity (I2 = 71.8, chi-square P = 0.029). The pooled summary diagnostic odds ratio was 56.54 (95% CI: 11.03-289.74) with no heterogeneity (I2 = 0.00%, chi-square P = 0.67). The diagnostic performance of the test was high with an area under the curve of (AUC) 0.980. CONCLUSIONS: p57KIP2 immunostaining is accurate when diagnosing CHM. It can be used as an adjunct test in a combination algorithmic approach. TWEETABLE ABSTRACT: A meta-analysis to evaluate the accuracy of p57KIP2 compared with genotyping to diagnose CHM.


Assuntos
Inibidor de Quinase Dependente de Ciclina p57/genética , Genótipo , Mola Hidatiforme/diagnóstico , Neoplasias Uterinas/diagnóstico , Feminino , Humanos , Mola Hidatiforme/genética , Imuno-Histoquímica , Gravidez , Sensibilidade e Especificidade , Neoplasias Uterinas/genética
6.
Int J Gynecol Cancer ; 17(6): 1205-14, 2007.
Artigo em Inglês | MEDLINE | ID: mdl-17506842

RESUMO

The detection of telomerase activity in cervix may provide information on cervical carcinogenesis and may be a marker to monitor cervical intraepithelial neoplasia transition. A quantitative systematic review was performed to estimate the accuracy of telomerase assay in cervical lesions. Studies that evaluated the telomerase test (telomerase repeated amplification protocol) for the diagnosis of cervix lesions and compared it to paraffin-embedded sections as the diagnostic standard were included. Ten studies were analyzed, which included 1069 women. The diagnostic odds ratio (DOR) for a positive telomerase test for low-grade squamous intraepithelial lesions (Lo-SIL) vs normal or benign lesions was 3.2 (95% CI, 1.9-5.6). The DOR for a positive telomerase test for high-grade squamous intraepithelial lesions (Hi-SIL) vs Lo-SIL, normal or benign lesions was 5.8 (95% CI, 3.1-10). For cervix cancer vs Hi-SIL, the DOR for a positive telomerase test was 8.1 (95% CI, 3.2-20.3) and for cervix cancer vs Lo-SIL, normal or benign lesions, it was 40.9 (95% CI, 18.2-91). Our data support the current hypothesis that telomerase may activate an early event in cervical carcinogenesis that could be associated with the initiation and progression of cervical lesions.


Assuntos
Telomerase/metabolismo , Displasia do Colo do Útero/enzimologia , Neoplasias do Colo do Útero/enzimologia , Feminino , Humanos , Razão de Chances , Sensibilidade e Especificidade , Displasia do Colo do Útero/diagnóstico , Neoplasias do Colo do Útero/diagnóstico
7.
Heart ; 92(2): 166-9, 2006 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-15890766

RESUMO

OBJECTIVE: To determine whether dietary supplementation with alpha linolenic acid (ALA) can modify established and emerging cardiovascular risk markers. DESIGN: Systematic review and meta-analysis of randomised controlled trials identified by a search of Medline, Embase, Cochrane Controlled Trials Register (CENTRAL), and the metaRegister of Controlled Trials (mRCT). PATIENTS: All human studies were reviewed. MAIN OUTCOME MEASURES: Changes in concentrations of total cholesterol, low density lipoprotein (LDL) cholesterol, high density lipoprotein (HDL) cholesterol, very low density lipoprotein (VLDL) cholesterol, triglyceride, fibrinogen, and fasting plasma glucose, and changes in body mass index, weight, and systolic and diastolic blood pressure. RESULTS: 14 studies with minimum treatment duration of four weeks were reviewed. ALA had a significant effect on three of the 32 outcomes examined in these studies. Concentrations of fibrinogen (0.17 micromol/l, 95% confidence interval (CI) -0.30 to -0.04, p = 0.01) and fasting plasma glucose (0.20 mmol/l, 95% CI -0.30 to -0.10, p < 0.01) were reduced. There was a small but clinically unimportant decrease in HDL (0.01 mmol/l, 95% CI -0.02 to 0.00, p < 0.01). Treatment with ALA did not significantly modify total cholesterol, triglycerides, weight, body mass index, LDL, diastolic blood pressure, systolic blood pressure, VLDL, and apolipoprotein B. CONCLUSIONS: Although ALA supplementation may cause small decreases in fibrinogen concentrations and fasting plasma glucose, most cardiovascular risk markers do not appear to be affected. Further trials are needed, but dietary supplementation with ALA to reduce cardiovascular disease cannot be recommended.


Assuntos
Doenças Cardiovasculares/sangue , Ácido alfa-Linolênico/administração & dosagem , Glicemia/metabolismo , Pressão Sanguínea/fisiologia , Peso Corporal/fisiologia , Doenças Cardiovasculares/dietoterapia , Doenças Cardiovasculares/fisiopatologia , Colesterol/sangue , Suplementos Nutricionais , Fibrinogênio/análise , Humanos , Fatores de Risco , Triglicerídeos/sangue
8.
JSLS ; 6(3): 195-7, 2002.
Artigo em Inglês | MEDLINE | ID: mdl-12166754

RESUMO

BACKGROUND: Over the years, hysteroscopy has been increasingly performed for various gynecological disorders. In this study, we present a review of hysteroscopic procedures performed over a 2-year period analyzing the complications associated with it. METHODS: Seven hundred twenty-six hysteroscopic procedures performed at the Department of Gynecology and Obstetrics, University of Kiel over a period of 2 years were reviewed retrospectively using the GynReg database in the department. Indications, intraoperative diagnoses, and complications were particularly highlighted. RESULTS: The most common indications for the procedure were abnormal vaginal bleeding, endometrial ablation, polypectomy, and myomectomy. The most common findings were uterine polyps, submucous myoma, and hyperplastic endometrium. The complication rate was 1.65% of total hysteroscopies. False passage and uterine perforation were the most common acute complications. No late complications occurred. CONCLUSIONS: Correlating our data with that found elsewhere, we find hysteroscopy to be a safe, minimally invasive procedure with a very low rate of complications.


Assuntos
Histeroscopia/métodos , Feminino , Humanos , Histeroscopia/efeitos adversos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...